Your browser doesn't support javascript.
loading
Cost-effectiveness of prophylactic emicizumab versus prophylactic recombinant factor VIII in patients with moderate or mild hemophilia A without inhibitors in the United States.
Potnis, Kunal C; Viswanathan, Giri; Bona, Robert D; Ito, Satoko; Kempton, Christine L; Pandya, Ankur; Krumholz, Harlan M; Goshua, George.
Afiliação
  • Potnis KC; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Viswanathan G; Yale College, New Haven, Connecticut, USA.
  • Bona RD; Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, USA.
  • Ito S; Section of Hematology, Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven, Connecticut, USA.
  • Kempton CL; Department of Hematology and Medical Oncology and Hemophilia of Georgia Center for Bleeding and Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Pandya A; Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Krumholz HM; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
  • Goshua G; Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut, USA.
Am J Hematol ; 98(9): E247-E250, 2023 09.
Article em En | MEDLINE | ID: mdl-37401660
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Hemofilia A Limite: Adult / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Hemofilia A Limite: Adult / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023